Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gérard Babany

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Fundamental & Clinical Pharmacology|October 1, 2009
Ribavirin therapeutic drug monitoring: why, when and how?Françoise Stanke-Labesque, Véronique Loustaud-Ratti, Gérard Babany, et al.
Therapeutic Drug Monitoring|March 11, 2010
Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditionsPierre Marquet, François-Ludovic Sauvage, Véronique Loustaud-Ratti, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in FranceSylvie Deuffic-Burban, Gérard Babany, Isabelle Lonjon-Domanec, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 25, 2010
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized studyJean-Pierre Zarski, Nathalie Sturm, Hervé Desmorat, et al.
Hepatology (Baltimore, Md.)|May 21, 2014
Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis CLaure Elkrief, Pascale Chouinard, Noelle Bendersky, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2011
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatmentVéronique Loustaud-Ratti, Paul Carrier, Annick Rousseau, et al.
Gastroenterology|March 29, 2011
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial)Stéphane Chevaliez, Christophe Hézode, Alexandre Soulier, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Fundamental & Clinical Pharmacology|October 1, 2009
Ribavirin therapeutic drug monitoring: why, when and how?Françoise Stanke-Labesque, Véronique Loustaud-Ratti, Gérard Babany, et al.
Therapeutic Drug Monitoring|March 11, 2010
Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditionsPierre Marquet, François-Ludovic Sauvage, Véronique Loustaud-Ratti, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in FranceSylvie Deuffic-Burban, Gérard Babany, Isabelle Lonjon-Domanec, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 25, 2010
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized studyJean-Pierre Zarski, Nathalie Sturm, Hervé Desmorat, et al.
Hepatology (Baltimore, Md.)|May 21, 2014
Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis CLaure Elkrief, Pascale Chouinard, Noelle Bendersky, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2011
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatmentVéronique Loustaud-Ratti, Paul Carrier, Annick Rousseau, et al.
Gastroenterology|March 29, 2011
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial)Stéphane Chevaliez, Christophe Hézode, Alexandre Soulier, et al.
Pageof 1